Millendo develops novel and disease modifying treatments for specialty and orphan endocrine diseases... Read more
Millendo develops novel and disease modifying treatments for specialty and orphan endocrine diseases... Read more
News
Jul 02, 2021
MarketScreener
Millendo Therapeutics: Millendo Therapeutics : Amendment to Current Report (SEC Filing - 8-K/A)
Jun 28, 2021
MarketScreener
Millendo Therapeutics: Tempest Closes Merger with Millendo and Completes PIPE Financing
Jun 23, 2021
MarketScreener
Millendo Therapeutics: Millendo Therapeutics : Tempest and Millendo Announce Stockholder Approval of Merger (Form 8-K)
May 04, 2021
Benzinga
Millendo Therapeutics: MILLENDO ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of MLND and Encourages Investors to Contact the Firm
Apr 27, 2021
MarketScreener
Millendo Therapeutics: SHAREHOLDER ALERT: WeissLaw LLP Investigates Millendo Therapeutics, Inc.
Apr 14, 2021
Benzinga
Millendo Therapeutics: INVESTIGATION ALERT: Halper Sadeh LLP Investigates TLND, MLND, ORBC, FI; Shareholders are Encouraged to Contact the Firm
Apr 07, 2021
Business Wire
Press Release: Millendo Therapeutics : MILLENDO INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Millendo Therapeutics, Inc. - MLND
Apr 05, 2021
Benzinga
Millendo Therapeutics: SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Millendo Therapeutics, Inc. Merger
Mar 31, 2021
Global Legal Chronicle
Millendo Therapeutics: Tempest Therapeutics' Merger With Millendo Therapeutics
Mar 31, 2021
centralcharts
Press Release: Millendo Therapeutics : Millendo Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Millendo Therapeutics, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm - MLND
